European Penny Stocks To Watch In May 2026

The European stock markets have experienced a positive week, with the pan-European STOXX Europe 600 Index climbing by 3.00% amid hopes for de-escalation in the Middle East. This backdrop of cautious optimism presents an intriguing opportunity for investors to explore lesser-known segments of the market, such as penny stocks. While traditionally associated with smaller or newer companies, penny stocks can offer unique growth potential at lower price points when supported by strong financials and fundamentals.

Here’s a peek at a few of the choices from the screener.

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Kerlink SA offers network infrastructure solutions for the Internet of Things (IoT) market across various regions including Europe, the Middle East, Africa, the Asia-Pacific, and the Americas, with a market cap of €9.39 million.

Operations: Revenue segments for the company are not reported.

Market Cap: €9.39M

Kerlink SA, with a market cap of €9.39 million, reported sales of €14.68 million for 2025, up from €11.67 million the previous year, while reducing its net loss to €2.03 million from €3.77 million. Despite being unprofitable and having a high debt-to-equity ratio of 534.4%, Kerlink’s short-term assets exceed both its short and long-term liabilities, providing some financial stability. The company has a positive cash runway exceeding three years due to growing free cash flow but faces high share price volatility and negative return on equity at -99.95%.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Aramis Group SAS operates in the online sale of used vehicles across France, Belgium, the United Kingdom, Austria, Italy, and Spain with a market cap of €255.40 million.

Operations: The company’s revenue is primarily derived from Refurbished Cars (€1.48 billion), followed by Pre-Registered Cars (€556.04 million), B2B (€141.32 million), and Services (€125.09 million).

Market Cap: €255.4M

Aramis Group SAS, with a market cap of €255.40 million, operates in the online sale of used vehicles across Europe and has shown mixed financial performance. Despite its stable short-term asset coverage over liabilities and satisfactory net debt to equity ratio of 19.3%, the company experienced a significant drop in net income to €0.065 million for H1 2026 from €6.39 million the previous year, impacted by a large one-off loss of €5.6 million. The group’s strategic brand unification across five countries aims to enhance its market presence and operational efficiency, supporting sustainable mobility through refurbished vehicle sales.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Biohit Oyj is a biotechnology company that produces and distributes acetaldehyde-binding products, diagnostic tools, and systems for research institutions, healthcare, and industry globally, with a market cap of €38.77 million.

Operations: The company’s revenue primarily comes from its Diagnostic Kits and Equipment segment, which generated €15.73 million.

Market Cap: €38.77M

Biohit Oyj, with a market cap of €38.77 million, has shown promising growth in the biotechnology sector. The company recently gained attention with its GastroPanel test, which significantly reduced endoscopy waiting lists by 87% in Chile, underscoring its potential to improve healthcare efficiency globally. Financially stable with no debt and short-term assets exceeding liabilities, Biohit has grown earnings by 6.6% over the past year—outpacing industry averages—though this is below its five-year trend. Despite high weekly volatility and a low return on equity of 18.3%, Biohit trades at a substantial discount to estimated fair value.

Taking Advantage

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ENXTPA:ALKLK ENXTPA:ARAMI and HLSE:BIOBV.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com